{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:54:05Z","timestamp":1781592845881,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for glycemic control and weight management in patients with type 2 diabetes and obesity, and their use has become increasingly common among candidates for elective plastic surgery. As a result, plastic surgeons are frequently encountering patients receiving GLP-1 RA therapy in the setting of metabolic and inflammatory comorbidities that may influence perioperative risk. This focused review examines the existing literature on GLP-1 RAs and contextualizes their biologic effects with considerations relevant to elective plastic surgery. A review of studies identified through PubMed, MEDLINE, and ClinicalKey was performed, with emphasis on the effects of GLP-1 RAs on chronic inflammation, immune signaling, endothelial function, and tissue biology in populations with metabolic or inflammatory disease. Across preclinical and clinical studies, GLP-1 RAs have been associated with attenuation of chronic inflammatory signaling, including reductions in circulating inflammatory markers and modulation of immune cell activity. Clinical benefits have been reported in conditions frequently encountered in plastic surgery practice, such as metabolic syndrome, polycystic ovary syndrome, and inflammatory skin diseases; however, direct evidence evaluating postoperative outcomes in surgical populations remains limited. Rather than acting on the acute postoperative healing response, GLP-1 RAs primarily influence chronic metabolic and inflammatory disease states that contribute to surgical risk. Understanding these effects may assist plastic surgeons in the perioperative setting, as GLP-1 RA therapy becomes increasingly prevalent in elective practice.<\/jats:p>\n                  <jats:p>Level of Evidence: 3 (Therapeutic)<\/jats:p>\n                  <jats:p\/>","DOI":"10.1093\/asj\/sjag064","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:48:29Z","timestamp":1774615709000},"page":"753-758","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0722-972X","authenticated-orcid":false,"given":"Niki K","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Henriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H","family":"Carruthers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Woodberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026061602134349200_sjag064-B1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026061602134349200_sjag064-B2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026061602134349200_sjag064-B3","doi-asserted-by":"publisher","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026061602134349200_sjag064-B4","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026061602134349200_sjag064-B5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061602134349200_sjag064-B6","first-page":"42","article-title":"A review of glucagon-like peptide-1 in dermatology","volume":"18","author":"Patino","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026061602134349200_sjag064-B7","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026061602134349200_sjag064-B8","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026061602134349200_sjag064-B9","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"2026061602134349200_sjag064-B10","doi-asserted-by":"publisher","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026061602134349200_sjag064-B11","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2021.3.14","article-title":"Exendin-4 differentially modulates essential functions of human dermal fibroblasts under normoglycemic and hyperglycemic conditions","volume":"72","author":"Wolak","year":"2021","journal-title":"J Physiol Pharmacol"},{"key":"2026061602134349200_sjag064-B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr Rev"},{"key":"2026061602134349200_sjag064-B13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"2026061602134349200_sjag064-B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/phar.70005","article-title":"The potential role of GLP-1 receptor agonists in osteoarthritis","volume":"45","author":"Ryan","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026061602134349200_sjag064-B15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026061602134349200_sjag064-B16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"2026061602134349200_sjag064-B17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/diseases13050127","article-title":"A closer look at the dermatological profile of GLP-1 agonists","volume":"13","author":"Persson","year":"2025","journal-title":"Diseases"},{"key":"2026061602134349200_sjag064-B18","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"key":"2026061602134349200_sjag064-B19","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026061602134349200_sjag064-B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"2026061602134349200_sjag064-B21","doi-asserted-by":"publisher","first-page":"14791641251322909","DOI":"10.1177\/14791641251322909","article-title":"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: a TriNetX database study","volume":"22","author":"Lewis","year":"2025","journal-title":"Diab Vasc Dis Res"},{"key":"2026061602134349200_sjag064-B22","doi-asserted-by":"publisher","first-page":"ojaf022","DOI":"10.1093\/asjof\/ojaf022","article-title":"Glucagon-like peptide-1 receptor agonists: friend or foe of aesthetic medicine?","volume":"7","author":"Rosenbloom","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"2026061602134349200_sjag064-B23","doi-asserted-by":"publisher","first-page":"629e","DOI":"10.1097\/PRS.0000000000011418","article-title":"Emerging role of semaglutide and GLP-1 agonist medications in plastic surgery: a note of caution","volume":"154","author":"Borab","year":"2024","journal-title":"Plast Reconstr Surg"},{"key":"2026061602134349200_sjag064-B24","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1007\/s00266-025-04703-4","article-title":"GLP-1 agonists in plastic surgery: impact on aesthetic outcomes\u2014two case reports","volume":"49","author":"Taraschi","year":"2025","journal-title":"Aesthetic Plast Surg"},{"key":"2026061602134349200_sjag064-B25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.soard.2024.08.033","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"20","author":"Kindel","year":"2024","journal-title":"Surg Obes Relat Dis"},{"key":"2026061602134349200_sjag064-B26","doi-asserted-by":"publisher","first-page":"ojaf056","DOI":"10.1093\/asjof\/ojaf056","article-title":"\u201cOzempic face\u201d in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions","volume":"7","author":"Daneshgaran","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"2026061602134349200_sjag064-B27","doi-asserted-by":"publisher","first-page":"442e","DOI":"10.1097\/PRS.0000000000012082","article-title":"Letter to the editor: medical weight management considerations in plastic surgery","volume":"156","author":"Koenig","year":"2025","journal-title":"Plast Reconstr Surg"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjag064\/67680565\/sjag064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/46\/7\/753\/67680565\/sjag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/46\/7\/753\/67680565\/sjag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:13:50Z","timestamp":1781590430000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/46\/7\/753\/8565883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjag064","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,30]]}}}